194 related articles for article (PubMed ID: 21544866)
41. Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents.
Yates AJ; Gutierrez GE; Smolens P; Travis PS; Katz MS; Aufdemorte TB; Boyce BF; Hymer TK; Poser JW; Mundy GR
J Clin Invest; 1988 Mar; 81(3):932-8. PubMed ID: 3343349
[TBL] [Abstract][Full Text] [Related]
42. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies.
Esbrit P; Alcaraz MJ
Biochem Pharmacol; 2013 May; 85(10):1417-23. PubMed ID: 23500550
[TBL] [Abstract][Full Text] [Related]
43. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study.
Horwitz MJ; Tedesco MB; Sereika SM; Garcia-Ocaña A; Bisello A; Hollis BW; Gundberg C; Stewart AF
Osteoporos Int; 2006 Feb; 17(2):225-30. PubMed ID: 16151606
[TBL] [Abstract][Full Text] [Related]
44. PTHrP enhances the secretory response of PTH to a hypocalcemic stimulus in rat parathyroid glands.
Lewin E; Almaden Y; Rodriguez M; Olgaard K
Kidney Int; 2000 Jul; 58(1):71-81. PubMed ID: 10886551
[TBL] [Abstract][Full Text] [Related]
45. Parathyroid hormone-related protein and calcium phosphate metabolism.
Law F; Ferrari S; Rizzoli R; Bonjour JP
Pediatr Nephrol; 1993 Dec; 7(6):827-33. PubMed ID: 8130117
[TBL] [Abstract][Full Text] [Related]
46. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
Ma YL; Cain RL; Halladay DL; Yang X; Zeng Q; Miles RR; Chandrasekhar S; Martin TJ; Onyia JE
Endocrinology; 2001 Sep; 142(9):4047-54. PubMed ID: 11517184
[TBL] [Abstract][Full Text] [Related]
47. [Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis].
Takeuchi Y
Clin Calcium; 2011 Jan; 21(1):28-32. PubMed ID: 21187591
[TBL] [Abstract][Full Text] [Related]
48. Parathyroid hormone-related protein, parathyroid hormone, and vitamin D in hypercalcemia of malignancy.
Motellón JL; Javort Jiménez F; de Miguel F; Jaras MJ; Díaz A; Hurtado J; Esbrit P
Clin Chim Acta; 2000 Jan; 290(2):189-97. PubMed ID: 10660809
[TBL] [Abstract][Full Text] [Related]
49. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.
Morony S; Capparelli C; Lee R; Shimamoto G; Boone T; Lacey DL; Dunstan CR
J Bone Miner Res; 1999 Sep; 14(9):1478-85. PubMed ID: 10469275
[TBL] [Abstract][Full Text] [Related]
50. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
51. Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.
Gafni RI; Brahim JS; Andreopoulou P; Bhattacharyya N; Kelly MH; Brillante BA; Reynolds JC; Zhou H; Dempster DW; Collins MT
J Bone Miner Res; 2012 Aug; 27(8):1811-20. PubMed ID: 22492501
[TBL] [Abstract][Full Text] [Related]
52. Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors.
Yaghoobian J; Morieux C; Denne MA; Bouizar Z; Ureña P; de Vernejoul MC
Horm Metab Res; 1998 May; 30(5):249-55. PubMed ID: 9660083
[TBL] [Abstract][Full Text] [Related]
53. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor.
Divieti P; John MR; Jüppner H; Bringhurst FR
Endocrinology; 2002 Jan; 143(1):171-6. PubMed ID: 11751606
[TBL] [Abstract][Full Text] [Related]
54. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G
J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532
[TBL] [Abstract][Full Text] [Related]
55. Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium, phosphate, parathyroid hormone (PTH), and PTH-related peptide levels.
Kovacs CS; Chik CL
J Clin Endocrinol Metab; 1995 Oct; 80(10):3036-42. PubMed ID: 7559893
[TBL] [Abstract][Full Text] [Related]
56. Skeletal recovery after weaning does not require PTHrP.
Kirby BJ; Ardeshirpour L; Woodrow JP; Wysolmerski JJ; Sims NA; Karaplis AC; Kovacs CS
J Bone Miner Res; 2011 Jun; 26(6):1242-51. PubMed ID: 21308774
[TBL] [Abstract][Full Text] [Related]
57. Physiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R.
Martin TJ; Sims NA; Seeman E
Endocr Rev; 2021 Jul; 42(4):383-406. PubMed ID: 33564837
[TBL] [Abstract][Full Text] [Related]
58. Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton.
Stewart AF
J Bone Miner Res; 2002 May; 17(5):758-62. PubMed ID: 12009005
[TBL] [Abstract][Full Text] [Related]
59. Human parathyroid hormone (PTH)-related protein and human PTH: comparative biological activities on human bone cells and bone resorption.
Fukayama S; Bosma TJ; Goad DL; Voelkel EF; Tashjian AH
Endocrinology; 1988 Dec; 123(6):2841-8. PubMed ID: 2848688
[TBL] [Abstract][Full Text] [Related]
60. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
